Core Insights - MasterCraft Boat Company is returning as an official sponsor of the 2025 American Century Championship (ACC) in Lake Tahoe, showcasing its premium towboat lineup and engaging in various high-impact activations [1][2] Sponsorship and Activations - The company has been a sponsor for six years and will feature flagship models XStar 23 and XStar 25 during the event [1] - Key activations include a $300,000 hole-in-one prize, a national sweepstakes in collaboration with Travis Mathew, Ogio, and Callaway, and the philanthropic initiative "Surf to Save Lives" supporting St. Jude Children's Research Hospital [1][6] Prize and Promotions - The hole-in-one challenge at Hole 12 offers a fully loaded 2024 MasterCraft X24, valued at over $300,000 [3] - The X24 features advanced technology and luxury amenities, emphasizing its performance and design [4] Philanthropic Initiatives - "Surf to Save Lives" will track minutes logged by celebrities and athletes riding behind MasterCraft boats, contributing to a $75,000 donation commitment [6] - Childhood cancer survivor and MasterCraft athlete Alexa Score will lead demonstrations and support fundraising efforts [7] Product Display and Partnerships - MasterCraft will display the XStar 23 and XStar 25 at Hole 17, alongside a Chevrolet Silverado, highlighting the partnership with General Motors [8][9] - The XStar models include innovative features such as the Z100 tower and MAAX Audio for enhanced performance [9] Post-Event Activities - Following the ACC, MasterCraft will host two on-water activations in Tahoe, allowing attendees to experience the latest boat lineup [10][13] Company Background - MasterCraft Boat Holdings, Inc. is a leading innovator in premium recreational powerboats, with a history of industry-leading innovation since its founding in 1968 [11][12]

Welcome back. Stocks near some session highs. Every sector currently green except energy led by consumer discretionary this morning.Joining us here at Post9 is Tom Lee, Fundstrat Global Adviserss, head of research and Fundstrat Capital chief investment officer, also a CNBC contributor. Tom, it's good to have you. Welcome.Talk about confounding expectations, wouldn't you say. What do you make of this morning's action. Well, you know, in some ways it's not a surprise because as you know, like Art Cashion had ...

What what is this latest injectable. Why is it better. It's a milestone moment, Becky, in in the history of HIV.Yes. Tuggo is is potentially the best tool we've had yet and and a number of great tools that could potentially end the epidemic. And the reason why is this is a first of its kind.Um medicine for preventing HIV that's given only twice a year. Uh and in clinical trials, it provided almost 100% protection against HIV, which is really unheard of. So, it's a it's one of the most important scientific b ...

Drug Development & Efficacy - Gilead's new injectable is the first of its kind for HIV prevention, administered only twice a year [3] - Clinical trials showed almost 100% protection against HIV [3][19] - The injectable addresses compliance issues associated with daily pills, where only about 50% of people taking pills are compliant [5] Market & Public Health Impact - There are still 30,000 new HIV infections a year in the United States and 13 million worldwide [6] - Over 700 new cases occur weekly in the US, with about 100 HIV-related deaths [6] - Certain regions, like the Southern United States, and demographics, such as women, Black and Latino men in the South, are disproportionately affected [7] Pricing & Accessibility - The injectable is priced roughly in line with other branded PrEP medicines [9] - Preventing an HIV infection can save as much as $11 million in lifetime costs [9] - Over 90% of existing PrEP medicines are covered by insurance companies [10] - Gilead has programs for uninsured individuals and those needing co-pay support [10] - Licensing agreements with six generic manufacturers will provide medicines to over 120 low and middle-income countries [11] Patent & Generics - The injectable has standard patent protection for 12 to 15 years [8] - Generic versions will be available in other countries in about two years, but not in the US for 12 years [12]

Core Insights - Teva Pharmaceutical Industries Ltd. announced the final analysis of the PEARL Phase 4 migraine prevention study, demonstrating that AJOVY (fremanezumab) showed sustained effectiveness over a two-year period in reducing migraine frequency, duration, and severity [1][3] Study Overview - The PEARL study was a 24-month real-world observational study involving 1,140 patients, predominantly female (87.25%), with 33.1% having episodic migraine (EM) and 66.9% chronic migraine (CM) [2][3] - The primary endpoint was a ≥50% reduction in Monthly Migraine Days (MMD) during the first 6 months of treatment, with secondary endpoints including mean change from baseline in MMD and treatment adherence [2] Effectiveness and Adherence - Over 66% of patients with EM and 51.6% with CM achieved the primary endpoint and benefitted from sustained migraine prevention for over 24 months [1][3] - Injection adherence rates remained high at approximately 90%, with over 75% (854 out of 1,129) of participants completing the study duration [1][3] Safety and Tolerability - The final analysis confirmed the favorable long-term safety and tolerability of fremanezumab, consistent with its known safety profile from previous studies [1][3] - The data supports the continued clinical use of fremanezumab for migraine prevention, particularly in populations with high disease impact [1][3] Clinical Implications - The findings underscore the importance of real-world studies in shaping clinical practice and highlight the critical role of CGRP-pathway therapies in improving patient outcomes, especially given that migraine is the second leading cause of disability worldwide [1][3]

A macroeconomic factor is an economic, environmental, or geopolitical event that broadly affects a regional or national economy. https://t.co/yhPnyaMG9y ...

Core Insights - Gilead Sciences, Inc. (GILD) received FDA approval for lenacapavir, branded as Yeztugo, a twice-yearly injectable HIV-1 capsid inhibitor for pre-exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV in adults and adolescents weighing at least 35kg [1][7][10] - Yeztugo is the first and only twice-yearly PrEP option available in the United States, representing a significant advancement in HIV prevention [1][10] - The approval was based on late-stage studies, PURPOSE 1 and PURPOSE 2, which demonstrated that ≥99.9% of participants who received Yeztugo remained HIV-negative [2][8] Company Performance - Year to date, GILD shares have increased by 18.6%, contrasting with a 4% decline in the industry [4] - The approval of Yeztugo enhances Gilead's HIV portfolio, especially as its other prevention drug, Truvada, faces generic competition [12] Competitive Landscape - Yeztugo's long-acting dosing aims to improve PrEP uptake by addressing adherence challenges and stigma associated with daily oral medications [7][10] - Gilead's flagship drug, Biktarvy, holds over 51% of the treatment market share in the United States, indicating strong market positioning [11] - The approval of Yeztugo is expected to catalyze uptake among historically underserved populations, providing a competitive advantage over daily oral pills [11][10] Regulatory and Market Developments - Yeztugo was granted Breakthrough Therapy Designation and has also received validation from the European Medicines Agency for marketing authorization [9] - The approval of long-acting injectable forms of PrEP, such as Yeztugo and ViiV Healthcare's Apretude, indicates a growing trend in HIV prevention strategies [13][14]

Core Viewpoint - Lucid Diagnostics has partnered with Hoag to enhance access to EsoGuard esophageal precancer testing, aiming to combat the rising incidence of esophageal cancer in Orange County [1][2]. Company Overview - Lucid Diagnostics Inc. is a commercial-stage cancer prevention medical diagnostics company and a subsidiary of PAVmed Inc., focusing on patients with gastroesophageal reflux disease (GERD) who are at risk of developing esophageal precancer and cancer [3]. - The EsoGuard® Esophageal DNA Test is the first and only commercially available tool designed for early detection of esophageal precancer in at-risk patients, performed through a non-invasive office procedure [3]. Partnership Details - Hoag has launched a comprehensive esophageal precancer testing program using Lucid's EsoGuard test, integrating it into its digestive health, primary care, and concierge medicine programs [1]. - The partnership is seen as a significant milestone in expanding access to EsoGuard within large healthcare systems, with expectations that it will serve as a model for other health systems [2]. Industry Context - The incidence of esophageal cancer has increased tenfold over the past four decades, highlighting the need for effective screening methods [2]. - The EsoGuard test offers a 3-minute non-endoscopic procedure aimed at identifying at-risk patients, which is critical for early intervention and potentially saving lives [2]. Hoag Overview - Hoag is a nonprofit regional healthcare delivery system in Orange County, California, recognized for its comprehensive personalized care and consisting of 1,800 physicians, 17 urgent care facilities, and two award-winning hospitals [5]. - It is ranked as the highest hospital in Orange County by U.S. News & World Report and is known for its specialized services in various health areas, including cancer and digestive health [5].

NORTH CHICAGO, Ill., June 18, 2025 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced positive topline results from its Phase 3 TEMPLE multicenter, randomized, double-blind, head-to-head study evaluating the tolerability, safety and efficacy of atogepant (QULIPTA® / AQUIPTA®, 60 mg once daily) compared to the highest tolerated dose of topiramate (50, 75 or 100 mg/day) in adult patients with a history of four or more migraine days per month.1 The study met the primary endpoint of treatment discontinuation d ...

Company Overview - RTX Corporation, formerly Raytheon Technologies, specializes in avionics, mission systems, and advanced defense technologies, including aircraft engines, air and missile defense, smart weapons, sensors, and cybersecurity tools [9] - The company has seen its stock reach all-time highs, outperforming the market with a year-to-date increase of over 28% [8] Financial Performance - RTX has a strong track record of exceeding earnings estimates, with a trailing four-quarter average earnings beat of 9.9% [11] - Analysts project a 4.2% increase in earnings for RTX in 2025, with expected revenues of $84.1 billion [11] - The company has a substantial backlog of $92 billion as of Q1, indicating solid revenue growth prospects for its defense business [12] Industry Context - RTX is part of the Zacks Aerospace – Defense industry group, which ranks in the top 28% out of approximately 250 industry groups, suggesting a favorable environment for defense stocks [10] - Defense stocks, such as RTX, are viewed as a means to mitigate volatility associated with geopolitical conflicts [16]